The Market Reports

Synopsis
The global market for Gene Delivery System was estimated to be worth US$ 11480 million in 2024 and is forecast to a readjusted size of US$ 61870 million by 2031 with a CAGR of 27.6% during the forecast period 2025-2031.
Gene Delivery System or Gene therapy is an experimental technique that uses genes to treat or prevent disease. In the future, this technique may allow doctors to treat a disorder by inserting a gene into a patient's cells instead of using drugs or surgery.
The gene delivery system market is experiencing rapid growth, primarily driven by advancements in gene therapy, personalized medicine, and biotechnology research. The increasing prevalence of genetic disorders, cancers, and rare diseases has fueled demand for targeted and effective gene-based treatments. Innovations in delivery vectors—such as viral systems (adenoviral, lentiviral) and non-viral methods (lipid nanoparticles, polymers, and electroporation)—are enabling more precise and efficient gene delivery. Additionally, the success of mRNA-based COVID-19 vaccines has accelerated investment and trust in nucleic acid delivery platforms. Supportive regulatory policies, increased R&D funding from both government and private sectors, and rising collaborations between pharmaceutical companies and academic institutions are further boosting the global gene delivery market.
Despite significant advancements, the gene delivery system market faces several complex challenges. One major hurdle is ensuring safe, efficient, and tissue-specific delivery of genetic material without triggering immune responses or toxicity. Viral vectors, while effective, can carry risks such as insertional mutagenesis or immunogenicity, limiting their long-term application. Non-viral vectors, on the other hand, often face limitations in transfection efficiency and stability. Manufacturing scalability and quality control also remain problematic, especially for complex delivery systems. Moreover, the high cost of gene therapies and the limited availability of clinical-grade vectors pose barriers to broader adoption, particularly in low- and middle-income countries. Navigating diverse regulatory frameworks globally adds another layer of complexity for companies operating across borders.
This report aims to provide a comprehensive presentation of the global market for Gene Delivery System, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Gene Delivery System by region & country, by Type, and by Application.
The Gene Delivery System market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Gene Delivery System.
Market Segmentation
By Company
Biogen
Novartis
Gilead Sciences
Sarepta Therapeutics
Alnylam Pharmaceuticals
Amgen
Spark Therapeutics
Akcea Therapeutics
Sunway Biotech
SIBIONO
AnGes
Orchard Therapeutics
Human Stem Cells Institute
Adaptimmune
Krystal Biotech
Vertex Pharmaceuticals
CSL Behring
Segment by Type
Viral Gene Delivery System
Non-viral Gene Delivery System
Segment by Application
Neurological Diseases
Cancer
Others
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Gene Delivery System company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Gene Delivery System in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Gene Delivery System in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Index